222 related articles for article (PubMed ID: 8019458)
1. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
Epstein JB; Reece DE
Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
[TBL] [Abstract][Full Text] [Related]
2. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease.
Epstein JB; Nantel S; Sheoltch SM
Bone Marrow Transplant; 2000 Mar; 25(6):683-7. PubMed ID: 10734307
[TBL] [Abstract][Full Text] [Related]
3. [Gran versus host disease with oral involvement: report of one case].
Rojas A G; González G N; Venables G C; Araos H D
Rev Med Chil; 2008 Dec; 136(12):1570-3. PubMed ID: 19350175
[TBL] [Abstract][Full Text] [Related]
4. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus.
Eckardt A; Starke O; Stadler M; Reuter C; Hertenstein B
Oral Oncol; 2004 Sep; 40(8):811-4. PubMed ID: 15288836
[TBL] [Abstract][Full Text] [Related]
5. The use of topical cyclosporin A in ocular graft-versus-host-disease.
Kiang E; Tesavibul N; Yee R; Kellaway J; Przepiorka D
Bone Marrow Transplant; 1998 Jul; 22(2):147-51. PubMed ID: 9707022
[TBL] [Abstract][Full Text] [Related]
6. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial.
Epstein JB; Truelove EL
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1996 Nov; 82(5):532-6. PubMed ID: 8936517
[TBL] [Abstract][Full Text] [Related]
7. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease.
Wolff D; Anders V; Corio R; Horn T; Morison WL; Farmer E; Vogelsang GB
Photodermatol Photoimmunol Photomed; 2004 Aug; 20(4):184-90. PubMed ID: 15238096
[TBL] [Abstract][Full Text] [Related]
8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
9. Oral graft vs. host disease in children--treatment with topical tacrolimus ointment.
Albert MH; Becker B; Schuster FR; Klein B; Binder V; Adam K; Nienhoff C; Führer M; Borkhardt A
Pediatr Transplant; 2007 May; 11(3):306-11. PubMed ID: 17430488
[TBL] [Abstract][Full Text] [Related]
10. Oral graft-versus-host disease.
Schubert MM; Correa ME
Dent Clin North Am; 2008 Jan; 52(1):79-109, viii-ix. PubMed ID: 18154866
[TBL] [Abstract][Full Text] [Related]
11. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases.
Epstein JB; Gorsky M; Epstein MS; Nantel S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Jan; 91(1):56-61. PubMed ID: 11174572
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment.
Spiryda LB; Laufer MR; Soiffer RJ; Antin JA
Biol Blood Marrow Transplant; 2003 Dec; 9(12):760-5. PubMed ID: 14677115
[TBL] [Abstract][Full Text] [Related]
13. Tretinoin for the treatment of cutaneous graft-versus-host disease.
Gryn J; Crilley P
Bone Marrow Transplant; 1990 Apr; 5(4):279-80. PubMed ID: 2104506
[TBL] [Abstract][Full Text] [Related]
14. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
Liem LM; van Noort JT; Goulmy E
Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
[TBL] [Abstract][Full Text] [Related]
15. Budesonide: a novel treatment for oral chronic graft versus host disease.
Elad S; Or R; Garfunkel AA; Shapira MY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Mar; 95(3):308-11. PubMed ID: 12627101
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features in patients with hepatic graft-versus-host disease.
Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
[TBL] [Abstract][Full Text] [Related]
17. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
19. [Photochemotherapy (PUVA) of acute graft-versus-host disease].
Reinauer S; Lehmann P; Plewig G; Heyll A; Söhngen D; Hölzle E
Hautarzt; 1993 Nov; 44(11):708-12. PubMed ID: 8276589
[TBL] [Abstract][Full Text] [Related]
20. PUVA therapy for drug-resistant graft-versus-host disease.
Atkinson K; Weller P; Ryman W; Biggs J
Bone Marrow Transplant; 1986 Dec; 1(2):227-36. PubMed ID: 3502781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
